The FDA has approved Novartis’ Mayzent (siponimod) multiple sclerosis pill for relapsing forms of the disease, dealing a potential blow to a much-delayed rival from Celgene.
Celgene has filed its highly anticipated oral MS drug ozanimod with the US regulator, more than a year after the FDA rejected it because of a bureaucratic foul-up.
Karuna Therapeutics has raised $68 million to further develop its neurology drug KarXT, which is in phase 2 clinical development for acute psychosis in patients with schizophrenia.
Acadia Pharmaceuticals may have thought it got out of trouble last year after an FDA safety investigation into its flagship Parkinson’s drug Nuplazid revealed no new risks – but documents h
The FDA has granted a fast review for Alexion Pharmaceuticals’ filing for its Soliris, as a treatment for a rare neurological disease that leads to worsening disability, blindness, paralysi
